Pulmologix
Recent Finacing
Series B
Recent Raise
$12.2M
Pulmologix develops an oral non-steroidal anti-asthmatic (ONSA) lead compound targeting allergic reactions that trigger early-onset asthma, preparing for Phase I and proof-of-concept clinical trials.
Highlights
Focus Areas
Clinical Trials
Health Care
Medical
Recent Investors
Financials
$12.2M
Total Raised
1
Funding round
4
Investors